Clinically Validated Probiotics
Complex Journey from Innovation to Patient impact
Elevating Drug Safety
From Snapshots to Movies
Why Sustainable Biomanufacturing Must Start Earlier in The Process
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Designing and Developing Green Drug Delivery Systems
Scientist, University of Kansas
Dr Sagar Salave is a Scientist at the University of Kansas USA specializing in mRNALNP therapeutics and viral vaccine formulation With a background in major pharmaceutical MNCs including Lupin and Ciron Drugs he possesses extensive expertise in drug discovery and nanotechnologydriven RD He serves as an Associate Editor for Applied Biochemistry and Biotechnology Journal Springer and sits on the Ed...
Articles
Approach for Producing Pharmaceuticals in Layer By Layer Fashion: Additive Manufacturing
D printing DP is a computeraided design with unique technology of prototyping layerbylayer fabricating D objects in the form of digital designs to achieve unmatched suppleness time conservation and extraordinary manufacturing capability of pharmaceutical dosage forms It works by depositing binding and polymerisation through layering until the desired object
Research Insights
A Review Of Global Initiatives To Fight Antibiotic Resistance And Recent Antibiotics' Discovery
Abstract Data from across the world have shown an overall decline in the antibiotic pipeline and continually rising resistance to all firstline and lastresort antibiotics The gaps in our knowledge of existing prevalence and mechanisms of antibiotic resistance ABR are all too well known Several decades of antibiotic abuse in humans animals and agricultural p
Case Studies
Effects Of Particle Size On The Triboelectrification Phenomenon In Pharmaceutical Excipients: An Experimental Case Study
Abstract Particle sizes play a major role to mediate charge transfer both between identical and different material surfaces The study probes in to the probable mechanism that actuates opposite polarities between two different size fractions of the same material by analyzing the charge transfer patterns of two different sizes of MCC Quantum scale calculations
Techno Trends
Shorla Oncology Introduced Novel SH-105 for the Treatment of Breast And Ovarian Cancer
Shorla Oncology has unveiled a groundbreaking drug SH designed to address breast and ovarian cancer SH marks a significant advancement as it offers a readytodilute alternative
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Effect of Size of Protein Therapeutics on Brain Pharmacokinetics following Systemic Administration
Chang supports the preclinical-to-clinical PKPD translation and human efficacious dose prediction of new biological entities at Boehringer Ingelheim. Dr. Chang obtained his MS and Ph.D. in Pharmaceutical Sciences at the University at Buffalo. Under Dr. Dhaval Shah’s mentorship, Dr. Chang investigated antibody and protein therapeutic disposition in the rat brain using large-poremicrodialysis and developed a translational brain PBPK model for monoclonal antibodies.
Dhaval K Shah is an Associate Professor of Pharmaceutical Sciences at the State University of New York at Buffalo. Prior to becoming the faculty Prof. Shah served as a Principle Scientist in the ‘Translational Research-Modeling & Simulation’ group at Pfizer Inc. His research focuses on understanding the determinants for the absorption, distribution, metabolism, and elimination (ADME) of protein therapeutics. His lab uses the principles of Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling & Simulation to support the discovery, clinical translation, and late phase development of novel biologics like engineered antibodies, multi-specific proteins, immuno-oncology agents, engineered T cells, and antibody-drug conjugates.
Shengjia Wu is a PhD student in the pharmaceutical sciences at the State University of New York at Buffalo. His research focuses on understanding and modeling the macromolecule distribution in the central nervous system.
Yingyi Li gained her master’s degree of pharmaceutical sciences in University at Buffalo. When Yingyi was a master student, she was working in Dr. Dhaval Shah’s lab and became more experienced in PBPK modeling. Yingyi is currently a scientist in the field of pharmacometrics and translational PK-PD in Enhanced Pharmacodynamics.
M&A, Partnerships & Ecosystem Models in Biopharma
Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Biopharma Therapeutics program, focusing on next-generation modalities and precision medicine. Her work spans market analytics, forecasting, competitive benchmarking, and strategy support for biopharma clients globally.
Redefining Therapeutics
Professor Mads Hald Andersen, DMSc, DScTech, PhD, is Director of the National Center for Cancer Immune Therapy, CCIT-DK, at Copenhagen University Hospital Herlev, Denmark. He discovered tumor microenvironment antigens and anti-regulatory T cells and defined their role in immune regulation. He initiated the immune modulatory vaccine concept and has authored more than 250 publications and 25 patents.
Nanotechnology as a Potential Therapeutic Strategy in Breast Cancer Management
Mr. Rahul Pal (Young Scientist), Ass. Prof. Department of Pharmacy, Jagannath University, Jaipur, holds B. Pharm, M. Pharm (Pharmaceutics), and PhD* at Chitkara University. He has authored 50+ publications, 8 textbooks, 12 edited book, secured 38 patents, 3 copyrights, received the Young Researcher Award (2025), and actively contributes as reviewer, editor, and speaker in national and international academic forums.
Why tier-2 and tier-3 cities are not included for clinical research
Co-Founder at DPHS Pvt. Ltd., Dr. Krutikesh Age is a researcher and a visionary committed towards propelling the field of clinical research and healthcare expansion in India. As the Co-founder of DPHS, Krutikesh manages varied key roles including Leadership, developing business and marketing strategies and Networking to name a few. It is through the deep understanding of clinical research and market dynamics that he has been instrumental in expanding the operations of DPHS in the past few years.
press releasesRead more...
Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery
Chai Discovery the AI company building a computeraided design suite for proteinbased therapeutics today announced a collaboration with Roche to use Chais AI models and platform in a number of drug discovery programs across its therapeutic areas
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED China Limited announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia AIHA Sovleplenib is a novel selective oral spleen tyrosine kinase Syk inhibitor
Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific
Abbott the global healthcare leader and Novo a global leader in treatments for serious chronic diseases announced an expanded strategic collaboration to increase access to originator semaglutide for people living with type diabetes across Asia Pacific Under the agreement Abbott will commercialise
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
Zuellig Pharma a leading healthcare solutions company in Asia announced the strategic acquisition of a specialized clinical supply facility in Hangzhou China strengthening its clinical sourcing capabilities to better support domestic and international clinical trials
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva Pharmaceutical Industries Ltd and Samsung Bioepis Co Ltd today announced that they have entered into a license and commercialization agreement for two FDAapproved immunology biosimilars infliximababda a biosimilar to Remicade infliximab and ETICOVO etanerceptykro a biosimilar to Enbrel etanerc...
EventsRead more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 25
Nov 2026BioPharma Deals - The Survival Series
Munich, Germany
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
LATEST NEWSRead more...
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
MindWalk Partners with Teva to Support Antibody Discovery Using AI
MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology
CStone Enters into Collaboration with Kimia Therapeutics to Advance Clinical Development of Novel Oncology Drug
CStone Pharmaceuticals has entered into a clinical development collaboration with USbased Kimia Therapeutics to advance a potential firstinclass drug candidate targeting the DNA damage response DDR pathway which plays an important role in the survival of solid tumour cells
DKSH and The Baker Company Partner to Expand Cell Culture and Microbiology Research
DKSH Business Unit Technology has entered into an exclusive distribution agreement with The Baker Company to make its Baker Ruskinn range of controlledenvironment technologies available to laboratories across Thailand The partnership aims to improve access to equipment used in cell culture tissue c...
Fresenius Enters into Agreement with WuXi Biologics to Expand Biosimilars Pipeline
Fresenius has entered into an exclusive development agreement with WuXi Biologics to expand its biosimilars pipeline and strengthen its biopharmaceutical business The partnership will give Fresenius access to WuXi Biologics capabilities in biologics research development and manufacturing
